p16基因甲基化对非小细胞肺癌术后化疗生存趋势的影响

Effects of p16 gene methylation on survival trend of non-small cell lung cancer with chemotherapy after surgical resection

目的:探讨p16基因甲基化与非小细胞肺癌术后吉西他滨联合顺铂化疗预后的关系。方法:随访55例非小细胞肺癌患者,其中术后接受2周期以上化疗者34例,未化疗者18例。检测患者肺癌组织p16基因甲基化,Ka-plan-Meier生存曲线分析比较各组中位生存时间。结果:在p16基因启动子区未甲基化的患者,化疗组与未化疗组中位生存期分别为39.2月、22.8月,差异具有统计学意义(P<0.05)。而p16基因甲基化的患者,化疗组与未化疗组中位生存期分别为22.1月、20.5月,差异无统计学意义(P>0.05)。结论:p16基因启动子区未甲基化的非小细胞肺癌患者可从术后常规化疗中获益。

Objective： To investigate the effects of p16 gene methylation on survival trend of non - small cell lung cancer with gemcitabine combined with cisplatin chemotherapy after surgical resection. Methods： Fifty - five patients with non - small cell lung cancer were involved in the study. Thirty - four cases received postoperative 2 cycles of chemotherapy, and other 18 cases without chemotherapy. Tumor was detected by p16 gene methylation. The median survival time of each group was compared by Kaplan- Meier survival curve analysis. Results Among patients with unmethylated p16 gene in the promoter region, the median survival time of chemotherapy group and non-chemotherapy group were 39.2 months and 22.8 months （P 〈0.05）. However, among patients with methylated p16 gene, the median survival time of chemotherapy group and non -chemotherapy group were 22. 1 months and 20.5 months, respectively（P 〉0.05）. Conclusion： Non -small cell lung cancer patients with unmethylated p16 gene can benefit from conventional chemotherapy after surgery.